These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2021002)

  • 21. An overview of the chemical modification of stroma free hemoglobin.
    Greenburg AG
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):71-5. PubMed ID: 3179495
    [No Abstract]   [Full Text] [Related]  

  • 22. Hemoglobin-based oxygen carriers: first, second or third generation? Human or bovine? Where are we now?
    Napolitano LM
    Crit Care Clin; 2009 Apr; 25(2):279-301, Table of Contents. PubMed ID: 19341909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hemoglobin-based oxygen-carrying solutions: close but still so far.
    Levy JH
    Anesthesiology; 2000 Mar; 92(3):639-41. PubMed ID: 10719939
    [No Abstract]   [Full Text] [Related]  

  • 24. S-nitrosylated polyethylene glycol-conjugated hemoglobin derivative as a candidate material for oxygen therapeutics.
    Nakai K; Sakuma I; Togashi H; Yoshioka M; Sugawara T; Satoh H; Kitabatake A
    Adv Exp Med Biol; 2003; 519():207-16. PubMed ID: 12675217
    [No Abstract]   [Full Text] [Related]  

  • 25. Artificial blood.
    Noble D
    Anal Chem; 1995 Jan; 67(1):31A-33A. PubMed ID: 7864389
    [No Abstract]   [Full Text] [Related]  

  • 26. ATP-hemoglobin: anomalous oxygen binding properties.
    McGarrity MJ; Er SS; Nightingale KA; Hsia JC
    J Chromatogr; 1987 Mar; 415(1):136-42. PubMed ID: 3584349
    [No Abstract]   [Full Text] [Related]  

  • 27. Basic science offers a challenge for developing hemoglobin based oxygen carriers into therapeutic agents.
    Bucci E
    Artif Cells Blood Substit Immobil Biotechnol; 2011 Aug; 39(4):206-13. PubMed ID: 21692690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The proton Bohr factor of native and crosslinker treated hemoglobins--its possible significance for the efficacy of hemoglobin based artificial oxygen carriers.
    Barnikol WK
    Adv Exp Med Biol; 1994; 361():363-70. PubMed ID: 7597959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Artificial blood: ancient dream, modern enigma.
    Winslow RM
    Nat Biotechnol; 1998 Jul; 16(7):621-2. PubMed ID: 9661191
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety evaluation of hemoglobin solutions.
    Fratantoni JC
    Prog Clin Biol Res; 1983; 122():111-5. PubMed ID: 6878352
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells.
    Taguchi K; Maruyama T; Otagiri M
    Drug Metab Rev; 2011 Aug; 43(3):362-73. PubMed ID: 21428698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Red cell substitutes.
    Winslow RM
    Semin Hematol; 2007 Jan; 44(1):51-9. PubMed ID: 17198847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxygen carriers ("blood substitutes")--raison d'etre, chemistry, and some physiology.
    Riess JG
    Chem Rev; 2001 Sep; 101(9):2797-920. PubMed ID: 11749396
    [No Abstract]   [Full Text] [Related]  

  • 34. Blood products have future despite recent setbacks.
    Brower V
    Nat Biotechnol; 1997 Jun; 15(6):507. PubMed ID: 9181565
    [No Abstract]   [Full Text] [Related]  

  • 35. Hemoglobin-based oxygen carriers as blood substitutes.
    Mozzarelli A
    Biochim Biophys Acta; 2008 Oct; 1784(10):1363-4. PubMed ID: 18809148
    [No Abstract]   [Full Text] [Related]  

  • 36. [Solutions of high-molecular modified hemoglobin: their physicochemical characteristics and biological evaluation].
    Bogomolova LG; Samsonov GV; Shcherba MM; Znamenskaia TV; Kuznetsova NP
    Probl Gematol Pereliv Krovi; 1979 Aug; 24(8):10-4. PubMed ID: 493259
    [No Abstract]   [Full Text] [Related]  

  • 37. Practical considerations in the development of hemoglobin-based oxygen therapeutics.
    Kim HW; Estep TN
    Curr Drug Discov Technol; 2012 Sep; 9(3):212-23. PubMed ID: 21726184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The use of perftoran in clinical medicine].
    Moroz VV; Kruylov NL; Ivanitskii GR; Kaidash AN; Onishchenko NA; Simanov VA; Vorob'ev SI
    Anesteziol Reanimatol; 1995; (6):12-7. PubMed ID: 8713413
    [No Abstract]   [Full Text] [Related]  

  • 39. Polymeric nanoparticles for hemoglobin-based oxygen carriers.
    Piras AM; Dessy A; Chiellini F; Chiellini E; Farina C; Ramelli M; Della Valle E
    Biochim Biophys Acta; 2008 Oct; 1784(10):1454-61. PubMed ID: 18452723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier.
    Chauvierre C; Marden MC; Vauthier C; Labarre D; Couvreur P; Leclerc L
    Biomaterials; 2004 Jul; 25(15):3081-6. PubMed ID: 14967542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.